WORLD WHO urges robust measures to reduce hepatitis burden in Africa

WORLD

WHO urges robust measures to reduce hepatitis burden in Africa

Xinhua

19:41, June 14, 2019

NAIROBI, June 14 (Xinhua) - The World Health Organization (WHO) on Friday called on African governments and partners to roll out robust interventions aimed at reducing the burden of hepatitis disease in the continent.

VCG111212872943.jpg

File photo: VCG

Olufunmilayo Lesi, communicable diseases specialist at WHO Regional Office for Africa, said hepatitis has emerged as a major public health threat in Africa.

"The burden of viral hepatitis in Africa is huge, but we must harness the power of technology, knowledge and public awareness to accelerate progress towards its elimination," Lesi told a media briefing in Nairobi.

WHO statistics show that more than 200,000 people in Africa die from complications linked to hepatitis B and C, such as cirrhosis and liver cancer, every year.

In sub-Saharan Africa, 60 million people are living with hepatitis B and an additional 11 million are infected with hepatitis C.

The two lethal strains of hepatitis that are transmitted through contaminated fluids can be contained through vaccination, screening of donated blood and improved hygienic practices, Lesi said.

"Blood safety, political commitment and domestic investments in hepatitis diagnosis, treatment and care is key to prevent deaths," she said.

African countries in 2016 adopted a four-year master plan to boost prevention, treatment and care of viral hepatitis.

Lesi said massive investments, combined with reforms in public health sector, are required to speed up the elimination of hepatitis in Africa.

"Country-specific action plans for controlling hepatitis infections should be implemented with urgency, and modern diagnostic tools are needed to help detect different strains of the disease to inform treatment," she said.

Capacity-building for health workers and awareness campaigns is key to strengthening response to high rate of hepatitis infection among high-risk groups like intravenous drug users, Lesi said.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue